George Pita
Known title: DirectorCIK: 0001293639
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Keybanc Lowers MasTec Price Target Amid Grid Infrastructure Focus. Keybanc maintains an Overweight rating on MasTec but lowered its price target to $320. Recent coverage highlights the company's exposure to grid infrastructure and data center growth, which analysts view as key drivers for industrial expansion. The stock is currently trading near its 52-week low, reflecting a pullback from its recent high of $441.43.
Transaction History
| OVV | ▲ Buy | Option Exercise | 3,510 | — | 5/21/2026 | View on chart |
| OVV | ▲ Buy | Option Exercise | 5,501 | — | 5/16/2025 | View on chart |
| OVV | ▲ Buy | Option Exercise | 2,800 | — | 8/9/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,213 | — | 5/17/2024 | View on chart |
| OVV | ▲ Buy | Option Exercise | 6,074 | — | 5/18/2023 | View on chart |
| MTZ | ▼ Sell | Tax Withholding | 20,940 | $1.8M | 3/19/2023 | View on chart |
| MTZ | ▲ Buy | Grant | 26,036 | $0 | 3/10/2023 | View on chart |
| OVV | ▲ Buy | Option Exercise | 4,499 | — | 5/18/2022 | View on chart |
| MTZ | ▲ Buy | Grant | 24,160 | $0 | 3/24/2022 | View on chart |
| MTZ | ▼ Sell | Tax Withholding | 10,025 | $831K | 3/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ovintiv receives multiple analyst price target raises
Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.
Ovintiv receives multiple analyst price target raises. Several research houses kept overweight or outperform ratings on Ovintiv and lifted their price targets, with Morgan Stanley moving to $71, Wells Fargo to $82, RBC to $90 and Truist to $77. The upgrades cite strong free‑cash‑flow generation from the company's Permian assets and the benefit of higher crude prices. The consensus analyst target is now about $78, above the current trading range.